Salvianolic acid B effectively inhibits the activity of GJB2 and enhances the sensitivity of anti‐PD1 therapy, which may provide insights into the development of novel combination therapeutic strategies for HCC (Figure 10). The gene discussed is GJB2; the disease is hepatocellular carcinoma.